n South African Pharmaceutical and Cosmetic Review - Sustained ARVs supply set to become a reality : pharmaceutical focus - HIV/Aids
|Article Title||Sustained ARVs supply set to become a reality : pharmaceutical focus - HIV/Aids|
|© Publisher:||New Media Publishing|
|Journal||South African Pharmaceutical and Cosmetic Review|
|Publication Date||May 2016|
In his 2016 State of the Nation Address (SONA), President Jacob Zuma announced the state owned pharmaceutical company, Ketlaphela, had been established as a 100 percent subsidiary of Pelchem. The company is set to participate in the supply of anti-retroviral drugs (ARVs) to the Department of Health from the 2016/17 financial year. According to a statement released by the Department of Science and Technology, shortly after the SONA, plans for Ketlaphela are to build South Africa's capacity to manufacture active pharmaceutical ingredients for key HIV medicines and other drugs. 'Over the next three years, R5.2 million has been allocated for Ketlaphela's development. This initiative will create jobs, transfer technology, and reduce the country's technology balance of payment in pharmaceuticals. It will also improve the delivery of high quality medicines for the treatment of high burden diseases such as cancer, tuberculosis and HIV', reads the statement.
Article metrics loading...